As emerging tumor components, intratumoral bacteria have been found in many solid
tumors. Several studies have demonstrated that different cancer subtypes have distinct …

Immunotherapy is one of the fastest developing areas in the field of oncology. Many
immunological treatment strategies for refractory tumors have been approved and marketed …

Background Nowadays, immune checkpoint inhibitors (ICIs) have become one of the
essential immunotherapies for cancer patients. However, the impact of antibiotic (ATB) use …

The clinical management of advanced malignancies of the upper and lower urinary tract has
been revolutionized with the advent of immune checkpoint blockers (ICBs). ICBs reinstate or …

Background: Immune checkpoint inhibitors (ICIs) have considerably improved patient
outcomes in various cancer types, but their efficacy remains poorly predictable among …

Treatment of metastatic renal cell carcinomas (mRCC) has drastically improved since the
advent of immunotherapy with immune checkpoint inhibitors (ICIs), with a significant …

Background Microbiome dysbiosis is considered a predictive biomarker of clinical response
in renal cell carcinoma (RCC), which can be regulated by antibiotics (ATB). Multiple studies …

Statins are commonly prescribed to reduce plasma cholesterol levels and risk of
cardiovascular events and mortality. Statin exposure may have cancer-preventive properties …

Systemic treatment options for patients with lung cancer have expanded in recent years, with
a number of immunotherapeutic strategies now in our treatment armamentarium. Toxicity of …

Recent advances in primary resistance mechanisms against imm... : Current Opinion in
Oncology Recent advances in primary resistance mechanisms against immune checkpoint …